Crossborder cooperation for innovative diagnosis of rare diseases in pediatricians (Q4298448): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Attach the beneficiary based on the string) |
(Changed an Item: Change because item Q4385890 was merged with Q4379882) |
||
Property / beneficiary | Property / beneficiary | ||
Revision as of 22:25, 24 June 2022
Project Q4298448 in Slovenia, Italy
Language | Label | Description | Also known as |
---|---|---|---|
English | Crossborder cooperation for innovative diagnosis of rare diseases in pediatricians |
Project Q4298448 in Slovenia, Italy |
Statements
723,564.81 Euro
0 references
880,244.0 Euro
0 references
82.2 percent
0 references
1 January 2020
0 references
31 December 2021
0 references
Istituto di Ricovero e Cura a Carattere Scientifico materno infantile Burlo Garofolo di Trieste
0 references
The so-called "rare diseases" do not receive adequate study and research attention from the scientific community and pharmaceutical industry. Many of these diseases occur in children and require continuous diagnostic and therapeutic efforts to improve the quality of life of affected children and to minimize the socio-economic impact on families and health system. In the Programme Area already exist consolidated clinical and scientific skills, especially in the cross-border axis between the IRCCS Burlo Garofolo of Trieste and the Pediatric clinic of the University of Ljubljana who already cooperate on research on some rare diseases such as immune-mediated inflammatory diseases. However, the following are still missing: a) Patient-centered diagnostic methods capable of defining specific individual pathological profiles and targeted treatments. b) A widespread knowledge throughout the territory on diagnostic and therapeutic possibilities in this sector. c) Efficient tools for knowledge /research results sharing, especially towards general practitioners, hospital doctors and patient associations. The project CATTEDRA intends to address these shortcomings by bringing together clinical centers, research centers and companies. (English)
0 references